Janssen and Bavarian Nordic sign $836m deal on Hep B and HIV vaccines

Janssen has signed a new deal with Bavarian Nordic worth up to $836 million to develop target vaccines for hepatitis B and HIV.

The projects will combine Bavarian Nordic’s MVA-BN technology with Janssen’s AdVac platform, and adds to two existing programmes being co-developed by the companies.

Janssen will pay $10 million upfront and its investment arm Johnson & Johnson Innovation (JJDC) will provide $33m in an equity investment by subscription of new Bavarian Nordic shares.

Bavarian Nordic will also receive payments for milestones in development, regulatory and sales milestones up $836 million, in addition to royalties on future sales.

Paul Chaplin

Bavarian Nordic’s Paul Chaplin

“We are very excited about this additional collaboration with Janssen, and proud to deploy our MVA-platform in the fight against two diseases with such an enormous impact on global health,” said Paul Chaplin, president & CEO of Bavarian Nordic.

“This agreement builds upon the science and data we have seen to date, which has shown the potential that a combination of our two platforms could serve many patients in a wide range of disease areas. We welcome this expansion of what has already been a fantastic relationship between our two companies.”

The companies first began collaborating in October 2014, when Janssen licensed MVA-BN for use in a heterologous prime-boost Ebola vaccine regimen. This was followed a second license for HPV in December 2015. Similar to these agreements, Janssen will be responsible for all clinical development, while manufacturing of MVA-BN is retained by Bavarian Nordic.

The new deals will help fund the research goals of the Copenhagen, Denmark-based company. Bavarian Nordic is developing a portfolio of active cancer immunotherapies, including PROSTVAC, currently in phase 3 development for advanced prostate cancer, and already has Bristol-Myers Squibb lined up as the product’s commercialisation partner if and when it reaches the market.

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.